Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases
- 1 August 2008
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Nephrology
- Vol. 23 (8) , 1269-1279
Abstract
Several case reports suggest that rituximab (RTX) could be effective in steroid-dependent nephrotic syndrome, but RTX efficacy has not yet been studied in a series of patients. Safety and efficacy of RTX were assessed in a multicenter series of 22 patients aged 6.3–22 years with severe steroid-dependent nephrotic syndrome or steroid-resistant but cyclosporin-sensitive idiopathic nephrotic syndrome. Patients were treated with two to four infusions of RTX. Seven patients were nephrotic at the time of RTX treatment. Peripheral B cells were depleted in all subjects. Remission was induced in three of the seven proteinuric patients. One or more immunosuppressive (IS) treatments could be withdrawn in 19 patients (85%), with no relapse of proteinuria and without increasing other IS drugs. RTX was effective in all patients when administered during a proteinuria-free period in association with other IS agents. When relapses occurred, they were always associated with an increase in CD19 cell count. Adverse effects were observed in 45% of cases, but most of them were mild and transient. This study suggests that RTX could be an effective treatment for severe steroid-dependent nephrotic syndrome.Keywords
This publication has 37 references indexed in Scilit:
- Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?Pediatric Nephrology, 2008
- Rituximab Failed to Improve Nephrotic Syndrome in Renal Transplant Patients With Recurrent Focal Segmental GlomerulosclerosisAmerican Journal of Transplantation, 2008
- Rituximab for refractory focal segmental glomerulosclerosisPediatric Nephrology, 2007
- Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?Pediatric Nephrology, 2007
- Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literatureClinical Neuropathology, 2007
- Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?Pediatric Nephrology, 2007
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006
- Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximabTransplant International, 2006
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytesCytometry, 1993